Title: Standardized uptake value of 18F-fluorodeoxyglucose in positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden

Author List: Sung Gwe Ahn[1*], Jong Tae Park[1*], Hak Min Lee[1], Hak Woo Lee[1], Tae Joo Jeon[2], Kyunghwa Han[3], Seung Ah Lee[5], Seung Myung Dong[6], Young Hoon Ryu[2], Eun Ju Son[4], and Joon Jeong[1]

* These authors equally contributed to this work.

Affiliation List: [1]Department of Surgery, [2]Department of Nuclear Medicine, [3]Biostatistics collaboration unit, Gangnam Medical Research Center, and [4]Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; [5]Department of Surgery, Eulji University College of Medicine, Seoul, Republic of Korea; [6]Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea

Sung Gwe Ahn (asg2004@yuhs.ac)

Jong Tae Park (pjt81@yuhs.ac)

Hak Min Lee (harumy@yuhs.ac)

Hak Woo Lee (mfreak82@nate.com)

Tae Joo Jeon (tjeonnm@yuhs.ac)

Kyunghwa Han (khhan@yuhs.ac)

Seung Ah Lee (seungah@eulji.ac.kr)

Seung Myung Dong (smdongstar@gmail.com)

Young Hoon Ryu (ryuyh@yuhs.ac)

Eun Ju Son (ejsonrd@yuhs.ac)

Joon Jeong (gsjjoon@yuhs.ac)

Corresponding author and full address for correspondence: Prof. Joon Jeong, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 135-720, Korea; e-mail: gsjjoon@yuhs.ac. Tel: 82-2-2019-3379; Fax: 82-2-3462-5994

ABSTRACT

Introduction: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of malignant tumors. Recent advances in molecular works suggest that tumor biology can well predict prognosis in breast cancer. We compared the ability of maximum standardized uptake values (SUV_{max}) from FDG-PET with tumor burden in predicting tumor recurrence for patients with breast cancer.

Methods: Between April 2004 and May 2009, 496 breast cancer patients who underwent pre-operative FDG-PET were retrospectively identified. SUV_{max} was obtained from FDG-PET, and the cut-off point was defined using a time-dependent receiver operator characteristic curve for recurrence-free survival (RFS). The primary end-point was RFS.

Results: In multivariate analysis for RFS, SUV_{max} carried independent prognostic significance (P = 0.012, hazard ratio (HR) 2.39, 95% confidence interval (CI) 1.20 to 4.76). When the patients were classified into four groups according to the combined factor of tumor size ($\leq$2 cm versus >2 cm) and SUV_{max} (<4 versus $\geq$4), RFS differed significantly (P <0.001). Similarly, SUV_{max} had prognostic value in combination with nodal status (negative versus positive) or stage (I versus II and III) (P <0.001 and P = 0.001, respectively). In hormone receptor-positive disease, SUV_{max} remained a significant prognostic factor for RFS based on multivariate analysis.

Conclusions: Our results highlight the prognostic value of FDG-PET in prediction of tumor relapse for breast cancer patients. Particularly in hormone receptor-positive disease, the tumor metabolic information provided by FDG-PET is more significantly correlated with prognosis than tumor burden.

INTRODUCTION

Tumor burden, represented by tumor size and the number of involved lymph nodes, is the most important prognostic factor for breast cancer recurrence [1,2] because advanced-stage tumors are more likely to have distant metastases. In this genomic era, rapid advances in translational research have greatly improved our understanding of breast cancer biology. This work provides us with the tools that can identify the intrinsic subtype of breast cancers and discriminate a prognosis according to the subtypes [3], highlighting the clinical availability of tumor biology in breast cancer prognosis [4,5]. These studies provide evidence that small tumors with undesirable biology can lead to a worsen prognosis rather than large tumors with favorable biology. Therefore, to deliver more effective personalized medicine approaches to individual patients, there is an increasing need to evaluate cancer with tumor biology integration, as well as simple anatomical staging.

18F-fluorodexoyglucose positron emission tomography (FDG-PET) is a useful tool in prediction of tumor recurrence, as well as for providing relevant anatomical information because this imaging study well reflects tumor biology [6,7]. It is one of new tools capturing tumor biology without an invasive procedure. The degree of FDG uptake reflects the metabolic characteristics of tumor and can be used as a prognostic factor in various malignancies. In breast cancer, studies have shown the contribution of tumor biology to increased FDG uptake [8-10], and have demonstrated that FDG uptake is associated with aggressive tumor characteristics [11,12].

As like other molecular markers were compared or integrated with tumor burden, we wondered whether a prognostic power of current clinical parameters improves when the biologic information of FDG-PET is combined with them. In this retrospective study, we evaluated the potential of FDG uptake as a prognostic indicator in breast cancer as compared to and in combination with tumor burden.

METHODS

Patient selection

Between April 2004 and May 2009, one thousand and fifty-three women consecutively underwent surgery for breast cancer. Of these 1,053 patients, 835 underwent preoperative FDG-PET as a part of their routine preoperative staging. Patients were excluded on the basis of the following criteria: known bilateral breast cancer (n=31); preoperative chemotherapy (because chemotherapy can affect tumor characteristics related to FDG uptake) (n=94); ductal carcinoma in situ (n=135); and distant metastases at initial assessment (n=42). Of these patients, 501 women of interest were identified. Patients missing data for any IHC marker were excluded (n=3). Patients with an IHC score of 2+ for HER2 but without fluorescence in situ hybridization (FISH) results for HER2 amplification were also excluded (n=2). Data for the remaining 496 patients were entered into the analysis (Figure 1).

For the IHC study of four markers, formalin-fixed, paraffin-embedded tissue sections obtained from the surgical specimens were stained with appropriate antibodies for estrogen receptor (ER) (Novocastra, Newcastle upon Tyne, UK), progesterone receptor (PR) (Novocastra), HER2 (Ventana Medical Systems, Tucson, AZ, USA), and Ki-67 (MIB-1; Dako, Glostrup, Denmark). For HER2 evaluation, membranous staining was graded with a score of 0, 1+, 2+, or 3+ [13]. HER2 status was considered positive with a score of 3+ and negative with a score of 0 or 1+. Tumors with a score of 2+ were sent for fluorescence in situ hybridization testing performed using the PathVysion HER2 DNA Probe Kit (Abbott-Vysis, Des Plaines, IL, USA).

The staging was performed according to the American Joint Committee on Cancer (AJCC), 7th edition. The modified Scarf-Bloom-Richardson grading system was used for tumor grading. Adjuvant systemic therapy and/or radiotherapy were administered according to the standard guidelines based on patient age, primary tumor characteristics, and axillary lymph node status. Endocrine therapy was given

to patients whose tumors were positive for hormone receptor expression. The follow-up protocol included planned regular visits every six months and requests for missed appointments with telephone calls were made to minimize the number of patients lost to follow-up and improve the accuracy of the survival data. The final update to the clinical database was made in December 2013.

The institutional review board (IRB) of Gangnam Severance Hospital, Yonsei University, Seoul, Korea, approved the study in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The IRB granted a waiver of written documentation of informed consent from all participants because of the retrospective design.

FDG-PET

Prior to FDG-PET, each patient was asked to fast for a minimum of 8 hours, and blood glucose levels were controlled to <130 mg/dl. Patients received an intravenous injection of 18F-FDG (0.14 mCi MBq) in the arm contralateral to the primary tumor. Sixty minutes after injection of 18F-FDG, whole-body emission scans were obtained using a Philips Allegro PET camera (Philips Medical Systems, Cleveland, Ohio, USA). Scans were obtained in the supine position with the arms raised. Attenuation-corrected transaxial images were reconstructed with an iterative transmission algorithm (row-action maximum likelihood 3D protocol) using a 3D image filter in a 128 × 128 matrix. For semi-quantitative evaluations, maximum standardized uptake value (SUV_{max}) was calculated by measuring the 18F-FDG absorption by tumors in the region of interest (ROI) using the following equation: SUV_{max} = [maximal radioactivity concentration in ROI (μCi/g) / injected dose (μCi)/patient's weight (kg)]. All FDG-PET scans were reviewed by two nuclear medicine radiologists who were blinded to survival data. SUV_{max} was obtained at the time of the imaging procedure.

Statistical analysis

The cut-off point of SUV_{max} was obtained by using the time-dependent ROC. Age is presented in the study as median value with a range and was compared by the Mann-Whitney U test. Discrete variables were compared by a chi-square test. The primary endpoint was recurrence-free survival (RFS), which was measured from the date of the first curative surgery to the date of the first tumor recurrence, including loco-regional recurrence or distant metastasis or death. Breast cancer-specific survival (BCSS) was measured from the date of the first curative surgery to the date of the last follow-up, or until death from breast cancer during the follow-up period. The Kaplan-Meier method was utilized to estimate RFS or BCSS. Using Harrell c-statistic [14], the concordance index (*c*-index) was calculated to measure the concordance for time-to event data, in which increasing values between 0.5 and 1.0 indicated improved prediction. The significant prognostic factors associated with RFS were selected based on the *c*-index (Additional File 1). The Cox's regression-hazard model was used for multivariable survival analysis. To assess the additional prognostic value of SUV_{max}, we used changes in the likelihood ratio values (LR-$\Delta\chi^2$) to quantitatively measure the relative amount of information for SUV_{max} compared to the model without SUV_{max}. The cut-off value of young age was defined as 35 in accordance with a previous Korean study [15]. The software used to perform these analyses was SPSS version 18 (SPSS; Chicago, IL) and R (http://www.r-projet.org). Statistical significance was defined by a *P*-value <0.05 or a 95% confidence interval (CI).

RESULTS

Definition of cutoff point for SUV_{max}

The cut-off point of SUV_{max} was obtained using the time-dependent ROC. The time-dependent ROC curve for SUV_{max} in relation to RFS yielded the area under the curve of 0.673 (95% CI, 0.588 to 0.753; Additional File 2). Youden's index was the highest for SUV_{max} of 4.2. Considering the clinical application, we defined the cutoff of SUV_{max} as 4.

Patient characteristics

A total of 496 patients with breast cancer were included in the analysis. The median age of the cohort was 48 years (range, 25-80 years). The median and mean SUV_{max} were 4.3 ± 3.1 and 3.2 (range, 0.3-32.9), respectively. When patients were divided into two groups according to SUV_{max}, these groups differed significantly in T stage, N stage, AJCC stage, which represent tumor burden. They also differed in characteristics reflecting tumor biology, including histologic grade, ER, PR, HER2, and Ki67. In considering the distribution of tumor subtypes, the group with high SUV_{max} had a higher rate of luminal B, HER2, and triple-negative subtypes. In contrast, the proportion of patients with the luminal A subtype was relatively low in the group with high SUV_{max} (Table 1). A higher rate of mastectomy was noted in the group with high SUV_{max} (Table 1).

Survival outcome

At a median follow-up of 6.03 years, tumors recurred in 40 patients. There were 13 cases with loco-regional recurrences, 25 cases with distant metastases, and two cases with combined local recurrence and distant metastases. During the follow-up period, 11 mortalities occurred, with eight breast cancer-specific mortalities and three non-breast cancer-specific mortalities. The probability of RFS at 6 years was 95.6% for patients with low SUV_{max} and 86.8% for patients with high SUV_{max}. High SUV_{max} was significantly predictive of decreased RFS (log-rank test, $P < 0.001$; Figure 1a). Furthermore, patients

with high SUV_{max} showed a reduced BCSS (log-rank test, $P = 0.007$; Figure 1b). When adjusted for age of diagnosis, T stage, nodal status, and ER status using the Cox-regression hazard model, high SUV_{max} was significantly associated with risk of tumor relapse (HR 2.39, 95% CI 1.20 to 4.76; Table 2). For this model, the Harrell *c*-index was 0.745. The *c*-index for the multivariate model without SUV_{max} was 0.724. The LR-$\Delta\chi^2$ showed a significant improvement of the additional prognostic utility of SUV_{max}.

Prognostic value of a combined SUV_{max} with tumor burden

Four patient groups were classified according to SUV_{max} and tumor size: (1) tumor size $\leq$ 2 cm and $SUV_{max} < 4$ (2) tumor size > 2 cm and $SUV_{max} < 4$ (3) tumor size $\leq$ 2 cm and $SUV_{max} \geq 4$ (4) tumor size > 2 cm and $SUV_{max} \geq 4$. The RFS of the four groups differed significantly ($P < 0.001$; Figure 2a). Within the groups of large tumor size (>2 cm) or small tumor size ($\leq$ 2 cm), RFS differed significantly according to the SUV_{max} ($P = 0.049$, $P = 0.009$, respectively). Conversely, within the groups of high SUV_{max} or low SUV_{max}, RFS did not differ according to tumor size ($P = 0.350$, $P = 0.096$, respectively).

Furthermore, SUV_{max} was significantly predictive of RFS in combination with nodal status ($P < 0.001$; Figure 2b). Node-positive patients with high SUV_{max} had worse outcomes, while node-negative patients with low SUV_{max} had better outcomes. Similarly, SUV_{max} combined with stage was significantly correlated with RFS ($P = 0.001$; Figure 2c).

SUV_{max} in luminal breast cancer

After the patients were divided into three subtypes (luminal, HER2, triple-negative), multivariate analysis for RFS was performed in each subtype. In luminal subtypes, which were defined as hormone receptor-positive breast cancer (ER positive and/or PR positive), SUV_{max} was found to be a significant

prognostic factor for RFS based on multivariate analysis (Table 3). However, in HER2 or triple-negative subtypes, SUV_{max} was not an independent prognostic factor (Additional File 3).

The prognostic value of SUV_{max} combined with tumor burden was also assessed in hormone receptor-positive breast cancer. When the patients were classified into four groups according to both combined factors, RFS differed significantly ($P < 0.001$; Figure 3a). There was no difference in RFS when stratified by tumor size within the groups with high SUV_{max} or low SUV_{max} ($P = 0.950$, $P = 0.688$, respectively). However, within the groups with small tumor sizes ($\leq$ 2 cm), a significantly reduced RFS was found in patients with high SUV_{max} ($P = 0.044$). In patients with large tumor sizes (>2 cm), RFS did not differ significantly according to SUV_{max} ($P = 0.065$) possibly due to the limited number of patients (n=122).

In luminal breast cancer, SUV_{max} was still predictive of RFS in combination with nodal status (negative vs. positive) or stage (I vs. II and III) ($P < 0.006$ and $P = 0.029$, respectively; Figure 3b, c).

DISCUSSION

The results of our study demonstrate the ability of SUV_{max}, to predict clinical outcomes in a large cohort of breast cancer patients undergoing FDG-PET. SUV_{max} carried independent prognostic significance in multivariate analysis for prediction of tumor relapse. An attempt to validate FDG uptake as a prognostic indicator in breast cancer has been made in previous studies [16-18]. However, failure to be validated as an independent prognostic factor [16], small number of patients [17], and analysis based on a Web-accessible risk-assessment model (Adjuvant! Online) [18] were limitations. Despite of these limitations, their studies provided evidence that that FDG uptake has potential as a prognostic marker in breast cancer, and it seems reasonable because tumors with increased glucose uptake show aggressive

tumor behaviors and high proliferating propensities [8-10]. Other studies have consistently shown that breast cancer with a high SUV_{max} is associated with ER negativity, high histologic grade, high Ki67, and triple-negative subtype [10-12], which is consistent with our data (Table 1). In support of the clinical significance of tumor biology associated glucose metabolism are recent studies showing that several signaling pathways implicated in cell proliferation and tumor progression also regulate metabolic pathways [19-22].

Particularly in the survival analyses using a combined factor with SUV_{max} and tumor burden, SUV_{max} showed a superior prediction of RFS in breast cancer compared with clinical tumor load. After four groups were formed using SUV_{max} and tumor size, within the groups with high or low SUV_{max}, tumor size did not provide additional prognostic differentiation (Figure 2a). However, within the groups with large or small tumor size, SUV_{max} improved the prediction of RFS. Similar results were seen when SUV_{max} was combined with nodal status or AJCC stage (Figure 2b,c). These findings suggest that when tumor biology is considered in addition to clinical tumor burden, prediction of breast cancer prognosis can be improved. SUV_{max} could provide powerful prognostic information about tumor relapse that is superior to considering only tumor burden, similar to the contribution of molecular subtype.

There are established molecular predictors reflecting tumor biology and predicting prognosis in breast cancer. Although the reason that the multi-gene assays are actively utilized for ER-positive disease has not been fully clarified, meta-analyses of various multigene breast cancer signatures concluded that their prognostic values are comparable when evaluated in hormone receptor-positive breast cancers, presumably due to the fact that the proliferation modules within these diverse gene signatures are a common driving force behind their overall prognostic performance [23,24]. By contrast, hormone receptor-negative breast cancers are more proliferative and are usually classified as high risk or

are not the appropriate target population for these prognostic signatures [23,24]. In the same context, our results show that the prognostic significance of SUV_{max} is distinct for luminal tumors (Table 3; Figure 3).

Furthermore, the mean SUV_{max} for the luminal subtype was the lowest, whereas those values for the HER-2 and triple-negative subtypes were comparatively higher (Additional File 4). This finding is concordant with previous reports comparing SUV_{max} between the IHC-defined subtypes [25]. It seems reasonable that HER2-positive or triple-negative tumors would show increased accumulation of FDG because these tumors have an aggressive phenotype and are associated with a high rate of proliferation, high Ki67, and high histologic grades. These associations between aggressive markers and high SUVmax were concordantly observed in our study (Table 1). Since HER2-positive or triple-negative tumors generally show high SUV_{max}, this may also lead to a reduced prognostic significance of SUV_{max} in these kinds of tumors.

We acknowledge several limitations inherent in our retrospective design. We are unable to control for variations in adjuvant therapy that may influence survival outcomes. Compared to the low SUV_{max} group, the patients in the high SUV_{max} group received more chemotherapy and less endocrine therapy, likely because they had more advanced-stage disease and ER negativity. The cut-off point for SUV_{max} defined within a single cohort also needs to be validated in an external cohort. However, there was not a significant difference in the number of patients receiving radiation treatment between the high SUV_{max} group and the low SUV_{max} group. There was also no survival difference between adjuvant chemotherapy or radiotherapy (Additional File 1).

CONCLUSIONS

Our study highlights the prognostic value of FDG-PET in predicting tumor relapse for breast cancer patients. We provide evidence supporting the potential utility of FDG-PET in combination with clinical tumor burden for the assessment of prognosis as well as evaluation of tumor location in patients with

breast cancer. These results lay the groundwork for future studies on the prognostic implication of SUV_{max} for breast cancer treatment.

List of abbreviations

18F-fluorodexoyglucose positron emission tomography: FDG-PET; Human epidermal growth factor receptor 2: HER2; Immunohistochemistry: IHC; Fluorescence in situ hybridization: FISH; Estrogen receptor: ER; Progesterone receptor: PR; Maximum standardized uptake value: SUV_{max}; Institutional review board: IRB; Region of interest: ROI; Recurrence-free survival: RFS; Breast cancer-specific survival: BCSS; Confidence interval: CI; HR: hazard ratio.

Competing interests

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (grant 2013R1A1A2007759).

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (grant 2013R1A1A2007759). Preparation of the final manuscript was done with the assistance of BioScience Writers LLC (Houston, TX).

Authors' contributions

All authors made substantial contributions to the conception and design, analysis and interpretation of data, and critical review of the manuscript. SGA and JJ conceived of the study, coordinated the data acquisition and analysis. SGA and JTP principally wrote the manuscript, and SGA, JTP, and KH mainly performed the analyses. TJJ and YHR performed FDG-PET and obtained SUV_{max}. HML, HWL, SAL, SMD, and EJS performed part of the analysis, contributed to the data, and helped to draft the manuscript. All authors have been involved in drafting the manuscript or revising it critically for important intellectual content. All authors approved the final manuscript.

REFERENCES

1. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G: **Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy.** *Breast Cancer Res Treat* 1996, **41**:177-185.
2. Carter CL, Allen C, Henson DE: **Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.** *Cancer* 1989, **63**:181-187.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: **Molecular portraits of human breast tumours.** *Nature* 2000, **406**:747-752.
4. Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Shin JH, Ko EY, Han BK, Ahn JS, Im YH: **Clinical relevance of TNM staging system according to breast cancer subtypes.** *Ann Oncol* 2011, **22**:1554-1560.
5. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM: **Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.** *J Clin Oncol* 2011, **29**:2628-2634.
6. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, Iwaisako K, Ikai I, Uemoto S: **Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma.** *Clin Cancer Res* 2007, **13**:427-433.

7. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA: **The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.** *J Thorac Cardiovasc Surg* 2005, **130**:151-159.
8. Ueda S, Kondoh N, Tsuda H, Yamamoto S, Asakawa H, Fukatsu K, Kobayashi T, Yamamoto J, Tamura K, Ishida J, Abe Y, Yamamoto M, Mochizuki H: **Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer.** *BMC Cancer* 2008, **8**:384.
9. Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu H, Sander C, Phelps ME, Brennan C, Port E, Huse JT, Graeber TG, Mellinghoff IK: **18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.** *Cancer Res* 2011, **71**:5164-5174.
10. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A: **Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.** *Cancer* 2008, **112**:995-1000.
11. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M: **The relationship between FDG uptake in PET scans and biological behavior in breast cancer.** *Breast Cancer* 2007, **14**:260-268.
12. Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, Zhuang H, Czerniecki B, Alavi A: **The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions.** *J Nucl Med* 2007, **48**:1266-1272.
13. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL: **Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.** *J Clin Oncol* 2007, **25**:5418-5425.
14. Harrell FE, Jr., Lee KL, Mark DB: **Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.** *Stat Med* 1996, **15**:361-387.

15. Han W, Kang SY; Korean Breast Cancer Society: **Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer.** *Breast Cancer Res Treat* 2010, **119**:193-200.
16. De Cicco C, Gilardi L, Botteri E, Fracassi SL, Di Dia GA, Botta F, Prisco G, Lombardo D, Rotmensz N, Veronesi U, Paganelli G: **Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?** *Breast* 2013, **22**:39-43.
17. Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S: **Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.** *J Cancer Res Clin Oncol* 2004, **130**:273-278.
18. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H: **Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.** *Jpn J Clin Oncol* 2008, **38**:250-258.
19. Vander Heiden MG, Cantley LC, Thompson CB: **Understanding the Warburg effect: the metabolic requirements of cell proliferation.** *Science* 2009, **324**:1029-1033.
20. Schieber MS, Chandel NS: **ROS links glucose metabolism to breast cancer stem cell and EMT phenotype.** *Cancer Cell* 2013, **23**:265-267.
21. Levine AJ, Puzio-Kuter AM: **The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes.** *Science* 2010, **330**:1340-1344.
22. Dang CV: **Links between metabolism and cancer.** *Genes Dev* 2012, **26**:877-890.
23. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M: **Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.** *Breast Cancer Res* 2008, **10**:R65.
24. Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC: **An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.** *Breast Cancer Res* 2013, **15**:R103.
25. Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, Kim WH, Lee SH, Kim MY, Kim JY, Seo M, Moon WK: **18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.** *Eur Radiol* 2014, **24**:610-8.

Additional files

Additional file 1 as .doc

We have provided details of our process for selecting variables and optimizing the multivariate model based on *c*-index.

Additional file 2 as .doc

Defined the cut-off value of SUV_{max}

Additional file 3 as .doc

1. Multivariate analysis for recurrence-free survival using the Cox-regression hazard model in HER2-positive disease or triple-negative disease.

2. Regimens for adjuvant chemotherapy used in our patients

Additional file 4 as .doc

SUV_{max} according to the intrinsic subtypes

Figure legends

Figure 1. Consort chart

Figure 2. Kaplan-Meier plots for disease-free survival and breast cancer-specific survival. All *P*-values were calculated by the log-rank test. (a) Recurrence-free survival (*P*=0.001) (b) Breast cancer-specific survival (*P* = 0.007).

Figure 3. Kaplan-Meier plots for recurrence-free survival according to combined factors with tumor burden and SUV_{max}. All *P*-values are calculated by the log-rank test. (a) Tumor size ($P < 0.001$) (b) Node status ($P < 0.001$) (c) Stage ($P = 0.001$).

Figure 4. Kaplan-Meier plots for recurrence-free survival according to a combined factor that includes both tumor burden and SUV_{max} in hormone receptor-positive cancer. All *P*-values are calculated by the log-rank test. (a) Tumor size ($P = 0.028$) (b) Node status ($P = 0.006$) (c) Stage ($P = 0.029$).

Table 1. Baseline characteristics according to SUV_{max}

Characteristics	All patients	High SUV	Low SUV	*P*-value[a]
Age at diagnosis, years				0.698
median (range)	48 (25-80)	48 (25-79)	49 (28-80)	
Histology				< 0.001
Invasive ductal carcinoma	416 (83.9)	173 (87.8)	243 (81.3)	
Invasive lobular carcinoma	22 (4.4)	1 (0.5)	21 (7.0)	
Mucinous carcinoma	13 (2.6)	2 (1.0)	11 (3.7)	
Tubular carcinoma	6 (1.2)	0 (0.0)	6 (2.0)	
Medullary carcinoma	4 (0.8)	4 (0.8)	0 (0.0)	
Other invasive carcinoma	35 (7.7)	17 (8.6)	18 (6.0)	
T classification				< 0.001
T1	270 (54.4)	68 (34.5)	202 (67.6)	
T2	217 (43.8)	126 (64.0)	91 (30.4)	
T3	9 (1.8)	3 (1.5)	6 (2.0)	
N classification				0.016
N0	329 (66.3)	115 (58.4)	214 (71.6)	
N1	123 (24.8)	59 (29.9)	64 (21.4)	
N2	30 (6.0)	17 (8.6)	13 (4.3)	
N3	14 (2.8)	6 (3.0)	8 (2.7)	
AJCC stage				< 0.001
I	200 (40.3)	42 (21.3)	158 (52.8)	
II	252 (50.8)	131 (66.5)	121 (40.5)	
III	44 (8.9)	24 (12.2)	20 (6.7)	
Histologic grade[b]				< 0.001
1	157 (35.0)	43 (22.8)	114 (44.0)	
2	199 (44.4)	78 (41.3)	121 (46.7)	
3	92 (20.5)	68 (36.0)	24 (9.3)	
ER				0.001
Positive	304 (61.3)	102 (51.8)	202 (67.6)	
Negative	192 (38.7)	95 (48.2)	97 (32.4)	
PR				0.005
Positive	293 (59.1)	97 (49.2)	196 (65.6)	
Negative	203 (40.9)	100 (50.8)	103 (34.4)	
HER-2[c]				< 0.001
Positive	127 (25.6)	72 (36.5)	55 (18.4)	
Negative	369 (74.4)	125 (63.5)	244 (81.6)	
Ki67				< 0.001
High	102 (20.6)	64 (32.5)	38 (12.7)	
Low	394 (79.4)	133(67.5)	261 (87.3)	
Subtypes				< 0.001
Luminal A	257 (51.8)	71 (36.0)	186 (62.2)	
Luminal B	71 (14.4)	39 (19.8)	32 (10.7)	

HER2	83 (16.7)	45 (22.8)	38 (12.7)	
Triple negative	85 (17.1)	42 (21.3)	43 (14.4)	
Surgery type				0.043
Mastectomy	352 (70.9)	150 (76.1)	202 (67.5)	
Breast-conservative surgery	144 (29.1)	47 (24.9)	97 (32.5)	
Adjuvant chemotherapy				< 0.001
Yes	347 (70.0)	162 (82.2)	185 (61.9)	
No	149 (30.0)	35 (17.8)	114 (38.1)	
Adjuvant endocrine therapy				0.001
Yes	332 (66.9)	114 (57.9)	218 (72.9)	
No	164 (33.1)	83 (42.1)	81 (27.1)	
Adjuvant radiotherapy				0.915
Yes	189 (38.1)	74 (37.6)	115 (38.5)	
No	307 (61.9)	123 (62.4)	184 (61.5)	

AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; SUV_{max}, maximum standardized uptake value.

[a] Chi-square test

[b] Data with missing values

[c] HER-2 positivity was defined by 3+ score on immunohistochemistry or amplification on fluorescence *in situ* hybridization.

Table 2. Multivariate analysis for recurrence-free survival using Cox-regression hazard model

Factors	Hazard ratio	95% CI	*P*-value
Age			0.144
Age > 35	Reference		
Age ≤ 35	1.86	0.81-4.25	
Tumor size			0.151
T ≤ 2 cm	Reference		
T > 2 cm	1.63	0.84-3.19	
Nodal status			0.038
Negative	Reference		
Positive	1.93	1.04-3.59	
Estrogen receptor			0.021
Positive	Reference		
Negative	2.19	1.12-4.27	
HER2			0.389
Negative	Reference		
Positive	1.33	0.69-2.57	
SUV_{max} [a]			0.013
Low (< 4)	Reference		
High (≥ 4)	2.39	1.20-4.76	

SUV_{max}, maximum standardized uptake value; HER2, human epidermal growth factor receptor-2.

[a] *P*=0.009 and chi-square=25.41 for the comparison with the analysis without SUV_{max} (by the likelihood-ratio test).

Table 3. Multivariate analysis for recurrence-free survival using Cox-regression hazard model in hormone receptor-positive disease

Factors	Hazard ratio	95% CI	*P*-value
Age			0.001
Age > 35	Reference		
Age ≤ 35	6.61	2.23-19.57	
Tumor size			0.706
T ≤ 2 cm	Reference		
T > 2 cm	0.815	0.28-2.35	
Nodal status			0.451
Negative	Reference		
Positive	1.49	0.53-4.21	
HER2			0.277
Negative	Reference		
Positive	1.87	0.61-5.77	
SUV_{max}			0.033
Low (< 4)	Reference		
High (≥ 4)	3.56	1.11-11.41	

SUV_{max}, maximum standardized uptake value; HER2, human epidermal growth factor receptor-2.


1,023 received breast cancer surgery at Gangnam Severance Hospital (April 2004-May 2009)
Excluded
-Patients without preoperative FDG-PET (n=217)
806 with FDG-PET
Excluded
-Preoperative chemotherapy (n=97)
-Bilateral (n=31)
-DCIS (n=135)
-Stage IV at diagnosis (n=42)
501 women
Excluded
-Patients missing data for any IHC marker (n=3)
-Patients with two positive for HER2 but without FISH for HER2 amplification (n=2)
496 with 4 IHC markers

Figure 1


A
100
90
80
70
60
Recurrence-free survival (%)
SUVmax < 4
SUVmax ≥ 4
P = 0.001
0
20
40
60
80
100
120
Months since operation
B
100
90
80
70
60
Breast cancer specific survival (%)
SUVmax < 4
SUVmax ≥ 4
P = 0.007
0
20
40
60
80
100
120
Months since operation

Figure 2


A
Recurrence-free Survival (%)
100
90
80
70
60
T≤2cm and SUVmax<4
T≤2cm and SUVmax<4
T≤2cm and SUVmax ≥4
T≤2cm and SUVmax≥4
P < 0.001
0 12 24 36 48 60 72 84 96 108 120
Months since operation
B
Recurrence-free Survival (%)
100
90
80
70
60
Node negative and SUVmax<4
Node positive and SUVmax<4
Node negative and SUVmax ≥4
Node positive and SUVmax≥4
P < 0.001
0 12 24 36 48 60 72 84 96 108 120
Months since operation
C
Recurrence-free Survival (%)
100
90
80
70
60
Stage I and SUVmax<4
Stage II or III and SUVmax<4
Stage I and SUVmax ≥4
Stage II or III and SUVmax≥4
P = 0.001
0 12 24 36 48 60 72 84 96 108 120
Months since operation

Figure 3


A
Recurrence-free Survival (%)
100
90
80
70
60
T≤2cm and SUVmax<4
T≤2cm and SUVmax<4
T≤2cm and SUVmax ≥4
T≤2cm and SUVmax≥4
P = 0.028
0 12 24 36 48 60 72 84 96 108 120
Months since operation
B
Recurrence-free Survival (%)
100
90
80
70
60
Node negative and SUVmax<4
Node positive and SUVmax<4
Node negative and SUVmax ≥4
Node positive and SUVmax≥4
P = 0.006
0 12 24 36 48 60 72 84 96 108 120
Months since operation
C
Recurrence-free Survival (%)
100
90
80
70
60
Stage I and SUVmax<4
Stage II or III and SUVmax<4
Stage I and SUVmax ≥4
Stage II or III and SUVmax≥4
P = 0.029
0 12 24 36 48 60 72 84 96 108 120
Months since operation

Figure 4

Additional files provided with this submission:

Additional file 1: Additional File R1_after.docx, 112K
http://breast-cancer-research.com/imedia/1306462099147981/supp1.docx
Additional file 2: Additional File R2.docx, 53K
http://breast-cancer-research.com/imedia/1400694645146992/supp2.docx
Additional file 3: Additional File R3.docx, 21K
http://breast-cancer-research.com/imedia/1849925282146965/supp3.docx
Additional file 4: Additional File R4.docx, 26K
http://breast-cancer-research.com/imedia/2036435507146991/supp4.docx